The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib

4084 Background: Gastric cancer is the most common malignancy in Oman. The proinflammatory cytokine IL-1-B polymorphisms have been associated with increased gastric cancer risk and shown to be of a prognostic value in advanced gastric cancer. Our aim is to study the prognostic significance of IL-1B- 31, -3954, IL-1RN- and GST T1/M1 polymorphisms in non-metastatic gastric cancer and correlate it with clinicopthological features. Methods: Genomic DNA was extracted from peripheral blood of 40 gastric cancer patients treated with adjuvant chemotherapy or chemoradiotherapy. The DNA samples were analyzed using TaqMan real-time polymerase chain reaction and 5’ nuclease assay. The deletion of GST T1/M1 genes was assessed by PCR. Results: The pathological stages were stage I = 1, stage II = 13, stage III = 22, stage IV = 3. The median follow up was 17 months. There was no prognostic significance for all the above polymorphisms in isolation. However, IL-1RN 2/2 IL-31 C/C genotypes (n = 13) were associated with worst outcome compared with IL-1RN L/L or 2/L and IL-31 T/T and T/C genotypes (n = 27). The median survival of IL-1RN 2/2 IL-31 C/C genotype was 16 months versus 63 months for IL-1RN L/L or 2/L and IL-31 T/T and T/C genotypes (p = 0.035). The IL-1RN 2/2 IL-31 C/C genotype correlated with signet ring pathology (p = 0.01) and non-distal gastric cancer location (p = 0.01). There was no significant association with T, N, or overall stage. Conclusion: These preliminary results suggest a prognostic value for IL-1-B polymorphisms in non-metastatic gastric cancer. No significant financial relationships to disclose.

Download Full-text

Epidemiological characteristics of peripheral circulating tumor cells and their relationship with the morbid state in gastric polyps and non-metastatic gastric cancer

10.21203/rs.3.rs-37177/v1 ◽

2020 ◽

Author(s):

Jun He ◽

Yingjie Xu ◽

Peng Sun ◽

Chen Qian ◽

Jun Yan ◽

...

Keyword(s):

Gastric Cancer ◽

Lymph Node ◽

Tumor Cells ◽

Peripheral Blood ◽

Metastatic Gastric Cancer ◽

Positive Lymph Node ◽

Invasive Group ◽

Gastric Polyps ◽

Significant Difference ◽

Group 1

Abstract BackgroundCirculating tumor cells (CTCs) can be detected in peripheral blood of many malignant tumor cases, but low numbers of CTCs can be detected in peripheral blood of healthy individuals as well as patients with benign tumors. It is not known whether peripheral CTC counts differ between patients with benign gastric diseases and those with gastric cancer. It is still unknown whether peripheral CTC counts can act as a superior factor to assess the clinicopathological stage in gastric cancer.MethodsComparative analysis of preoperative peripheral CTC counts was completed in patients with gastric polyps and non-metastatic gastric cancer. Correlation analysis was carried out between peripheral CTC counts and histological differentiation types, histopathological types, depth of tumor infiltration, positive lymph node metastasis rate and tumor markers (CEA, CA19-9 and CA72-4).ResultsPatients with gastric cancer had higher CTC counts than those with gastric polyps (3.05 ± 0.48/3.2 ml vs 0.69 ± 0.17/3.2 ml, P < 0.05). Over 84.62% of the higher CTC group (≤ 1/3.2 ml) were gastric polyp patients. A significant difference was observed between lower CTC counts group (≤ 1/3.2 ml) and higher CTC counts group (> 1/3.2 ml) diagnosed with either gastric polyps or gastric cancer (X2 = 9.67, P < 0.005). Significant difference was observed between moderate differentiation and poor differentiation in gastric cancer (X2 = 2.43, P < 0.05).The tissue pathological types distributions showed no statistically difference between two CTC counts group (P>0.05). Significant CTC counts difference was observed between mucous membrane invasive group and muscular layer invasive group in gastric cancer (3.00 ± 0.33/3.2 ml vs 1.4 ± 0.4/3.2 ml, P < 0.05). No significant CTC counts difference was observed in different positive lymph node ratios groups in gastric cancer (P>0.05). CTC counts could show higher positive ratio when compared with CEA, CA19-9 and CA72-4 respectively (X2 = 34.37, X2 = 36.89, X2 = 29.72, P < 0.001) or jointly (X2 = 16.71, P < 0.001) in gastric cancer.ConclusionsPeripheral CTC counts were different between patients with gastric polyps and patients with gastric cancer. CTC counts could act as an independent factor to assess the clinicopathological stage in gastric cancer. CTC counts might be more sensitive than routine tumor markers to reflect the existence of early gastric cancer.

Download Full-text

Prognostic Value of Systemic Immune Index in Patients with Metastatic Gastric Cancer

European Archives of Medical Research ◽

10.4274/eamr.galenos.2020.36449 ◽

2021 ◽

Vol 37 (2) ◽

pp. 95-100

Author(s):

Hacer Demir ◽

Yavuz Katırcılar ◽

İsmail Beypınar ◽

Saliha Karagöz Eren ◽

Mevlüde İnanç

Keyword(s):

Gastric Cancer ◽

Prognostic Value ◽

Metastatic Gastric Cancer

Download Full-text

The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy

Frontiers in Oncology ◽

10.3389/fonc.2021.655716 ◽

2021 ◽

Vol 11 ◽

Author(s):

Miaomiao Gou ◽

Yong Zhang ◽

Tiee Liu ◽

Tongtong Qu ◽

Haiyan Si ◽

...

Keyword(s):

Gastric Cancer ◽

Multivariate Analysis ◽

Prognostic Value ◽

Univariate Analysis ◽

Objective Response ◽

Progression Free Survival ◽

Metastatic Gastric Cancer ◽

Significant Prognostic Factor ◽

Angiogenic Therapy ◽

Pre Treatment

BackgroundBiomarkers such as prevailing PD-L1 expression and TMB have been proposed as a way of predicting the outcome of immunotherapy in patients with advanced gastric cancer (AGC) and metastatic gastric cancer (MGC). Our study aims to investigate whether there is a link between pretreatment hemoglobin (Hb) levels and survival to immunotherapy in patients with AGC and MGC.MethodsWe retrospectively reviewed patients with AGC or MGC treated at the oncology department of the Chinese PLA general hospital receiving PD-1 inhibitor. The Propensity Score Matching (PSM) (1:1) was performed to balance potential baseline confounding factors. Progression-free survival (PFS) and overall survival (OS) was analyzed among different Hb level (normal Hb group and decreased Hb group). Objective response rate (ORR), disease control rate (DCR) were also analyzed. Univariate analysis and multivariate analysis were performed further to validate the prognostic value of Hb level.ResultsWe included 137 patients with AGC and MGC who received PD-1 inhibitors (including Pembrolizumab, Nivolumab, Sintilimab, Toripalimab) in this study. After PSM matching, there were no significant differences between the two groups for baseline characteristics. Within the matched cohort, the median PFS was 7.8 months in the normal Hb level group and 4.3 months in the decreased Hb group (HR 95% CI 0.5(0.31, 0.81), P=0.004). The OS was 14.4 months with normal Hb level as compared with 8.2 months with decreased Hb level(HR 95% CI 0.59(0.37, 0.94), P=0.024). The ORR was 40.7% and DCR was 83.0% in the normal Hb group, while the ORR was 25.5% and DCR was 85.1% in the decreased Hb group. No significant differences were found in the ORR and DCR between the two groups (P=0.127, P=0.779). Univariate analysis and multivariate analysis showed that Hb level was only independent predictor for PFS and baseline Hb level was significant prognostic factor influencing the OS. Only when patients had normal Hb level, anti-pd-1 monotherapy or combined with chemotherapy was superior to anti-pd-1 plus anti-angiogenic therapy with respect to PFS (10.3 m vs 2.8 m, HR 95% CI 0.37(0.15, 0.95), P=0.031) and OS(15 m vs 5.7 m, HR 95% CI 0.21 (0.08, 0.58), P=0.001).ConclusionsOur study have demonstrated that pretreatment Hb level was an independent prognostic biomarker in term of PFS and OS with immunotherapy for AGC and MGC patients. Correction of anemia for GC patients as immunotherapy would be a strategy to improve the survival. More data was warranted to further influence this finding.

Download Full-text

Abstract B138: Prognostic value of PTEN loss for second-line paclitaxel treatment efficacy in metastatic gastric cancer

10.1158/1535-7163.targ-17-b138 ◽

2018 ◽

Author(s):

Kyoo Hyun Kim ◽

Jeong Hyun Jo ◽

Sejung Park ◽

Minkyu Jung ◽

Woo Sun Kwon ◽

...

Keyword(s):

Gastric Cancer ◽

Treatment Efficacy ◽

Prognostic Value ◽

Metastatic Gastric Cancer ◽

Second Line ◽

Pten Loss ◽

Paclitaxel Treatment

Download Full-text

1100 Peripheral blood lymphocite populations in advanced gastric cancer patients have predictive and prognostic value

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70393-3 ◽

2009 ◽

Vol 7 (2) ◽

pp. 114-115

Author(s):

R. Pazo Cid ◽

J. Lao Romera ◽

M. Lanzuela ◽

I. Gil ◽

A. Godoy ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Cancer Patients ◽

Peripheral Blood ◽

Prognostic Value ◽

Gastric Cancer Patients ◽

Predictive And Prognostic Value

Download Full-text

Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) mRNA expression in patients with metastatic gastric cancer receiving first-line chemotherapy

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.4547 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. 4547-4547

Author(s):

C. Pauligk ◽

R. Wirtz ◽

K. Steinmetz ◽

J. T. Hartmann ◽

N. Homann ◽

...

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Mrna Expression ◽

Prognostic Value ◽

Validation Cohort ◽

Metastatic Gastric Cancer ◽

Hazard Ratio ◽

Phase Iii ◽

Vegf Mrna ◽

Training Cohort

4547 Background: In preclinical tumor models, VEGF and MMP-9 induced each other, resulting in the enhancement of tumor angiogenesis and the formation of metastases. This study evaluated MMP-9 and VEGF in patients (pts) with metastatic gastric cancer. Methods: Patient tumor samples from a phase III trial of the AIO were prospectively collected. VEGF and MMP-9 mRNA were isolated from paraffin embedded tissues using a new patented method based on nanotechnology. The expression was then assessed by qRT-PCR and by immunohistochemistry (IHC). Results: A total of 137 (training cohort 96; validation cohort 41) out of 220 pts enrolled were analyzed. In the training cohort, increased MMP-9 levels were strongly associated with increased VEGF expression, resistance to chemotherapy and shorter progression-free and overall survival. At the cut-off with the highest predictive value, the rate of disease progression as best response associated with elevated MMP9 expression was 50% (vs. 22.4%; Fisher's test p=.027) and median overall survival (OS) was 3.1 months (vs. 8.7 months, log rank p=.0000165). This prognostic value for survival was maintained when data were analyzed in the multivariate setting (relative hazard ratio for death 3.67, p=.00045) or were categorized according to the quartile (p=.004) or median (p=.024) distributions for MMP-9. VEGF showed a prognostic effect in pts with low MMP-9 expression, only. In the validation cohort, the prognostic value of increased MMP-9 expression could be confirmed at the best cut off derived from the training cohort, with the hazard ratio for death being 3.45 (p=.02). Interestingly, in the IHC, stromal but not tumoral MMP-9 protein expression predicted survival (log rank p=.033). Conclusions: Tumoral MMP-9 mRNA expression levels are the first validated molecular prognostic factor in metastatic gastric cancer. These results have implications for novel anti-protease/ anti-VEGF treatment strategies. [Table: see text]

Download Full-text